• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Do No Harm: Stories of Life, Death and Brain Surgery review
Patients see neurosurgeons as gods, but what is the reality? Henry Marsh has written a memoir of startling candourWe go to doctors for help and healing; we don't expect them to make us worse. Most people know the aphorism taught to medical students, attributed to the ancient Greek Hippocrates but timeless in its quiet sanity: "First, do no harm." But many medical treatments do cause harm: learning how to navigate the risks of drug therapies, as well as the catastrophic consequences of botched or inadvised surgical operations, is a big part of why training doctors takes so long. Even the simplest of therapies carries the ri...
Source: Guardian Unlimited Science - March 19, 2014 Category: Science Authors: Gavin Francis Tags: The Guardian Private healthcare Culture Society Reviews Books Neuroscience UK news Hospitals NHS Source Type: news